Suchergebnisse - "Venkatakrishnan, Karthik"

PubPharm (267)

51

Method for enhancing pharmacokinetics or increasing plasma concentration of 3-((methylsulfonyl) amino)-2-(((4-phenylcyclohexyl) oxy) methyl) piperidine-1-carboxylic acid methyl ester or salt thereof using inhibitor of cytochrome P450

enthalten in: Europäisches Patentamt | 2022

von ROGER MICHEL | FESSLER HOLGER | LU HONG | +3

52

Designing phase I oncology dose escalation using dose-exposure-toxicity models as a complementary approach to model-based dose-toxicity models

enthalten in: CPT: pharmacometrics & systems pharmacology | 2022

von Pantoja, K. | Lanke, S. | Munafo, A. | +6

53

Model-informed approach for risk management of bleeding toxicities for bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1

enthalten in: Cancer chemotherapy and pharmacology | 2022

von Vugmeyster, Y. | Grisic, A. | Wilkins, J. | +5

54

Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors

enthalten in: Investigational new drugs | 2022

von Zhou, X. | Vaishampayan, U. | Mahalingam, D. | +7

55

Current Practices, Gap Analysis, and Proposed Workflows for PBPK Modeling of Cytochrome P450 Induction : An Industry Perspective

enthalten in: Clinical pharmacology and therapeutics | 2022

von Hariparsad, N. | Ramsden, D. | Taskar, K. | +20

56

Alternatives to rifampicin : A review and perspectives on the choice of strong CYP3A inducers for clinical drug-drug interaction studies

enthalten in: Clinical and translational science | 2022

von Bolleddula, J. | Gopalakrishnan, S. | Hu, P. | +2

57

사이토크롬 P450의 억제제를 사용하여 메틸 3-피페리딘-1-카르복실레이트 또는 그의 염의 약동학을 향상시키거나 혈장 농도를 증가시키기 위한 방법

enthalten in: Europäisches Patentamt | 2022

von FAESSEL HELENE | LU HONG | VENKATAKRISHNAN KARTHIK | +3

58

Model-informed approach for risk management of bleeding toxicities for bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1

enthalten in: Cancer chemotherapy and pharmacology | 2022

von Vugmeyster, Y. | Grisic, A. | Wilkins, J. | +5

59

Model-informed approach for risk management of bleeding toxicities for bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1

enthalten in: Cancer chemotherapy and pharmacology | 2022

von Vugmeyster, Y. | Grisic, A. | Wilkins, J. | +5

60

Population pharmacokinetic/pharmacodynamic joint modeling of ixazomib efficacy and safety using data from the pivotal phase III TOURMALINE-MM1 study in multiple myeloma patients

enthalten in: CPT: pharmacometrics & systems pharmacology | 2022

von Srimani, J. | Diderichsen, P. | Hanley, M. | +3